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Methylene blue and peritoneal
dialysis
To the Editor: I have read with interest the case presented
by Wu et al.1 regarding urinary bladder perforation
after implantation of a peritoneal dialysis (PD) catheter.
The colored picture showing methylene blue in the efﬂuent
dialysate in the PD bag is quite impressive for the general
practitioner, but nephrologists involved in the ﬁeld of PD may
express several objections regarding this approach.
There are several reports that methylene blue may be an
irritant to the peritoneum and cause chemical peritonitis,
and thus, it is not advisable to use it for diagnostic reasons
in PD.2,3 The unexpected glycosuria and the abdominal
computed tomography imaging should be sufﬁcient to
establish the correct diagnosis, as in other cases.4
The patient of Wu et al.1 was transferred to maintenance
hemodialysis. However, I would not consider the use of
methylene blue in PD for diagnostic reasons as a wise
approach, as the main focus of PD remains to preserve the
peritoneum for as long as possible.
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The Authors Reply: We appreciate Dr Fourtounas1 for his
interest in our work.2 We agree that the unexpected
glycosuria and the abdominal computed tomography imaging
highly suggested that the urinary bladder might be perforated
by the peritoneal dialysis (PD) catheter. However, we think
a conﬁrmatory test is still needed to make the decision
to remove a newly inserted PD catheter. The reason for
Dr Fourtounas’ objection to use methylene blue-stained
dialysate in PD patients is fear of chemical peritonitis. We
fully agree that nephrologists should try to preserve
peritoneum as long as possible. However, we searched the
literature on this issue and found only two case reports that
are also mentioned in the letter.1 In addition, we found seven
PD patients who have been reported to receive intraperitoneal
use of methylene blue-stained dialysate and video-assisted
thoracoscopic surgery to detect and repair their pleuroper-
itoneal communications.3–6 None of them developed chemical
peritonitis and all of them resumed PD well. Therefore,
whether the use of methylene blue-stained dialysate for
diagnostic purposes is contraindicated in PD patients is still a
matter of debate. Furthermore, in this patient, the immediate
presence of blue urine in the urinary bag indicated that most
of the methylene blue-stained dialysate was infused directly
into the urinary bladder, rather than the peritoneal cavity.
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Effects of angiotensin-converting
enzyme inhibitors and angiotensin
II receptor blockers on peritoneal
transport
To the Editor: I have read the excellent revision by Nessim
et al.1 entitled ‘The renin–angiotensin–aldosterone system in
peritoneal dialysis: is what is good for the kidney also good for
the peritoneum?’. In the part of the article where the authors
describe the potential strategies for peritoneal membrane
preservation, they stated that the ﬁrst study in this area with
human data was published in 2007 by Kolesnyk et al. in
Peritoneal Dialysis International.2 However, this is incorrect,
because the ﬁrst study, published in Nephron, about the
effects of angiotensin-converting enzyme inhibitors (ACEIs)
on peritoneal membrane transport was a short-term study
that included 12 diabetic patients on continuous ambulatory
peritoneal dialysis and that showed the decrease of peritoneal
protein losses with the oral administration of captopril, as
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